We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our
Cookie Policy
.
Accept
Label
Search
SKIP TO CONTENT
SKIP NAVIGATION
Drug News
Trending
Commercial Operations
GMPs
FDA Enforcement Actions
Inspections and Audits
Postmarket Safety
Quality
Regulatory Affairs
Research and Development
Submissions and Approvals
FDAnews
Device News
Trending
Commercial Operations
FDA Enforcement Actions
Inspections and Audits
Postmarket Safety
Quality
Regulatory Affairs
Research and Development
Submissions and Approvals
FDAnews
Books
FDAnews Books Library
Drug Books
Device Books
Training/Events
Webinar Training Pass
Events
Webinar Recordings
Resources
Form 483s Database
FDA Approved Drugs
CenterWatch
WCG Clinical
Sign In
Create Account
Sign Out
My Account
Home
»
Authors
» Robert J. Martin
Robert J. Martin
Products
PRODUCTS
Catalent Massachusetts, LLC
Robert J. Martin
,
Leanna M. Slarsky
, and
Daniel L. Zheng
Price:
$117.00
View
Regeneron Pharmaceuticals, Inc.
Robert J. Martin
and
Guerlain Ulysse
Price:
$117.00
View
Brigham and Women's Hospital
Robert J. Martin
Price:
$117.00
View
Alden Medical, LLC
Robert J. Martin
and
Jonah S. Ufferfilge
Price:
$117.00
View
Ipsen Bioscience, Inc.
Robert J. Martin
Price:
$117.00
View
Tedor Pharma, Inc.
Robert J. Martin
Price:
$117.00
View
PolyCarbon Industries, Inc.
Robert J. Martin
Price:
$117.00
View
Braintree Laboratories, Inc.
Erik W. Koester
and
Robert J. Martin
Price:
$117.00
View
Winder Laboratories, LLC
Robert J. Martin
Price:
$117.00
View
Ipsen Bioscience, Inc.
Robert J. Martin
and
Delaram Moshkelani
Price:
$117.00
View
View All Products by Robert J. Martin
Upcoming Events
21
Oct
MAGI@home Clinical Research Conference 2024
Featured Products
From QSR to QMSR: Meeting FDA’s New Requirements
FDA Oversight of Laboratory-Developed Tests — The Impact of the Final Rule
Featured Stories
Risk of 10 Obesity-Driven Cancers Reduced by GLP-1s, Study Says
Three Device Areas Added to CDRH’s Device-Advancing TAP Program
Third Alzheimer’s Drug Gets FDA Approval, Just as Diagnostic Criteria Expand
Draft Guidance Covers Using URRAs in Combo Product Applications
The Revised ICH E8:
A Guide to New Clinical Trial Requirements
Learn More